XTX Topco Ltd Acquires Shares of 25,495 Novavax, Inc. (NASDAQ:NVAX)

XTX Topco Ltd bought a new stake in Novavax, Inc. (NASDAQ:NVAX) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 25,495 shares of the biopharmaceutical company’s stock, valued at approximately $323,000.

Other institutional investors have also modified their holdings of the company. Amalgamated Bank grew its position in Novavax by 26.9% in the 2nd quarter. Amalgamated Bank now owns 4,887 shares of the biopharmaceutical company’s stock valued at $62,000 after buying an additional 1,036 shares during the last quarter. Edgestream Partners L.P. lifted its stake in shares of Novavax by 23.7% in the 1st quarter. Edgestream Partners L.P. now owns 12,753 shares of the biopharmaceutical company’s stock worth $61,000 after acquiring an additional 2,447 shares during the period. Banque Cantonale Vaudoise boosted its holdings in shares of Novavax by 500.0% in the second quarter. Banque Cantonale Vaudoise now owns 3,000 shares of the biopharmaceutical company’s stock valued at $38,000 after acquiring an additional 2,500 shares in the last quarter. Ameritas Investment Partners Inc. increased its stake in shares of Novavax by 31.6% during the first quarter. Ameritas Investment Partners Inc. now owns 11,298 shares of the biopharmaceutical company’s stock worth $54,000 after acquiring an additional 2,711 shares during the period. Finally, Signaturefd LLC raised its holdings in Novavax by 214.5% during the second quarter. Signaturefd LLC now owns 5,680 shares of the biopharmaceutical company’s stock worth $72,000 after purchasing an additional 3,874 shares in the last quarter. Institutional investors and hedge funds own 53.04% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have issued reports on the company. JPMorgan Chase & Co. boosted their target price on Novavax from $8.00 to $9.00 and gave the stock an “underweight” rating in a research report on Monday, August 12th. B. Riley reaffirmed a “buy” rating and set a $23.00 price objective (down previously from $25.00) on shares of Novavax in a report on Monday, August 12th. Finally, Bank of America raised their target price on Novavax from $12.00 to $18.00 and gave the company a “neutral” rating in a report on Friday, June 14th. One analyst has rated the stock with a sell rating, three have given a hold rating and two have given a buy rating to the company. Based on data from MarketBeat.com, Novavax has an average rating of “Hold” and an average target price of $15.80.

Novavax Price Performance

Shares of NASDAQ:NVAX opened at $12.15 on Friday. The firm has a market capitalization of $1.71 billion, a price-to-earnings ratio of -3.83 and a beta of 2.04. The business’s 50 day simple moving average is $12.77 and its 200-day simple moving average is $10.85. Novavax, Inc. has a 12 month low of $3.53 and a 12 month high of $23.86.

Novavax (NASDAQ:NVAX) last posted its earnings results on Thursday, August 8th. The biopharmaceutical company reported $0.99 EPS for the quarter, missing analysts’ consensus estimates of $1.82 by ($0.83). The business had revenue of $415.50 million during the quarter, compared to the consensus estimate of $458.57 million. During the same quarter last year, the firm posted $0.58 EPS. The business’s quarterly revenue was down 2.1% compared to the same quarter last year. On average, equities analysts anticipate that Novavax, Inc. will post -1.04 earnings per share for the current year.

About Novavax

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.